Retrospective Analysis of Ibrutinib Discontinuation and Outcomes in CLL in Trial vs Real-World Settings

December 3-6, 2016; San Diego, California
In this study, median PFS with ibrutinib was similar in the clinical trial and real-world settings, although more patients discontinued for treatment-related adverse events in the real-world setting.
Format: Microsoft PowerPoint (.ppt)
File Size: 539 KB
Released: December 5, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Celgene Corporation
Incyte
Merck & Co., Inc.
Seattle Genetics

Related Content

In this slideset from Clinical Care Options, experts provide insights on the optimal use of CAR T-cell therapy for lymphomas

Frederick L. Locke, MD Released: December 3, 2020

Downloadable slides on most current clinical data on frontline therapies for CLL.

Jeremy S. Abramson, MD, MMSc Released: December 3, 2020

CCO Conference Coverage of ASH 2020 with downloadable slides and experts’ commentaries of clinically relevant studies

Hanny Al-Samkari, MD John M. Burke, MD Jorge Cortes, MD Amy E. DeZern, MD, MHS Shaji Kumar, MD Sagar Lonial, MD person default Mark A. Schroeder, MD Jeff P. Sharman, MD Sujit Sheth, MD Srdan Verstovsek, MD, PhD Eunice S. Wang, MD Released: December 2, 2020

From Clinical Care Options (CCO), expert commentary on key new developments in CAR T-cell therapy and a preview of CAR T-cell data at ASH 2020

Michael Wang, MD Released: December 1, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue